VSIR and urinary bladder carcinoma: In mouse models of melanoma and bladder cancer, genetic deletion of Vsir or administration of anti-VISTA blocking antibodies has been shown to enhance T cell-mediated anti-tumour immune response and inhibit tumour growth [18–20].